-
Activation of PAR2 inhibits the expression of IL-10 in B cells, which can be reversed by treating B cells with Bcl2L12 shRNA-carrying liposomes.
-
BCL2L12 is a new prognostic biomarker for favorable outcome in diffuse large B-cell lymphoma patients on rituximab.
-
stress hormone cortisol suppresses p53 in hepatocellular carcinoma via enhancing Bcl2L12 expression
-
TNF-alpha suppresses IL-10 in peripheral B cells via up-regulating Bcl2L12 in patients with ulcerative colitis.
-
miR-125a-5p inhibits cell proliferation and induces apoptosis in colon cancer cells via targeting BCL2, BCL2L12 and Mcl-1.
-
Identify 50 novel BCL2L12 splice variants in human tumor cell lines.
-
Results show that high Bcl2L12 mRNA expression was associated with the high-grade breast cancer and triple-negative (TNBC) subtype. Also, the interplay between Bcl2L12 and its variant may be associated with high lymph node metastasis in non-TNBC tumors.
-
CD82 regulated BCL2L12 expression via STAT5A and AKT signaling and stimulated proliferation and engrafting of leukemia cells.
-
Bcl2L12 retains a BH3-like domain, which is important for its anti-apoptotic property.
-
Data indicate that BCL2-like 12 (proline rich) protein BCL2L12 mRNA levels can distinguish women with breast cancer from healthy controls.
-
Data indicate that BCL2L12 expression levels were associated with poor disease-free survival of the high-grade TaT1 bladder cancer patients.
-
Bcl2L12 was previously shown to inhibit apoptosis through binding to caspase 7.
-
cisplatin treatment induced a time-dependent apoptosis in glioblastoma cells, at least partially via downregulation of BCL2L12 gene expression.
-
Acute myeloid leukemia patients have a lower level of BCL2L12 gene expression.
-
Protein made from F17F mutant BCL2L12 transcript bound p53, inhibited UV-induced apoptosis more efficiently than WT BCL2L12, and reduced endogenous p53 target gene transcription.
-
results suggest BCL2L12 mRNA expression may serve as potential prognostic biomarker in tongue and/or larynx SCC, which principally constitute great majority of HNSCC cases worldwide.
-
Bcl2L12 expression efficiently discriminates chronic lymphocytic leukemia cases from healthy controls but did not reflect their clinical characteristics
-
BCL2L12 can be considered as a new independent prognostic and chemotherapy response marker in acute myeloid leukemia.
-
Molecular cloning of novel alternatively spliced variants of BCL2L12, a new member of the BCL2 gene family, and their expression analysis in cancer cells.
-
The BCL2L12(153-191) fragment directly interrupted GSK3beta mediated Tau phosphorylation.
